Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective observational study of ipragliflozin in patients with type 2 diabetes
jRCT1090220182Completed
- Sponsor
- Nagoya Medical Association
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ipragliflozin in type 2 diabetes mellitus (T2DM), sponsored by Nagoya Medical Association. Primary endpoints: Change in HbA1c from baseline to Week 24, Number of hypoglycemic episodes and 1 more. Started Jun 2014; status: completed.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1090220182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1090220182.